title: Recombinant hCG (OVIDREL) and recombinant interferon-(beta)1a (REBIF). (No. 13 in a series of articles to promote a better understanding of the use of genetic engineering).
authors: Serono International SA, 15 bis Chemin des Mines, CH-1202 Geneva, Switzerland. philippe.fonjallaz@serono.com
authors: P
authors: P
authors: Fonjallaz
authors: E
authors: E
authors: Loumaye
mesh_terms: D000818:Animals; D016466:CHO Cells; D006063:Chorionic Gonadotropin / Q000235:genetics / Q000494:pharmacology / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D006224:Cricetinae; D005260:Female; D006801:Humans; D007247:Infertility, Female / Q000188:drug therapy*; D015202:Protein Engineering / Q000379:methods*; D011994:Recombinant Proteins / Q000235:genetics / Q000627:therapeutic use*
chemical_list: D006063:Chorionic Gonadotropin; C412828:Ovidrel; D011994:Recombinant Proteins